Adaptimmune Therapeutics Shares Surge 50% Following CCO Departure Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: TipRanks
Severance Agreement: Adaptimmune Therapeutics reached a severance agreement with former CCO Cintia Piccina, granting her 12 months of pay totaling $473,800 and continued benefits from the Employee 2016 Share Option Scheme.
Termination Details: Piccina was terminated due to redundancy on August 8, 2025, with the severance agreement effective from August 23, 2025.
Stock Performance: Following the news, ADAP stock surged by 47.23% in pre-market trading after experiencing an 18.38% decline the previous Friday, though it remains down 88.98% year-to-date.
Analyst Ratings: Wall Street analysts have a consensus rating of Moderate Sell for Adaptimmune Therapeutics, with an average price target of 35 cents, indicating a potential upside of 488.24%.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
